Ra Capital Management, L.P. Sells 101,151 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 101,151 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $0.64, for a total transaction of $64,736.64. Following the completion of the sale, the insider directly owned 406,282 shares in the company, valued at approximately $260,020.48. The trade was a 19.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Trading Down 7.6%

Shares of NASDAQ HOWL opened at $0.58 on Thursday. The stock has a market cap of $28.38 million, a price-to-earnings ratio of -0.47 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 52 week low of $0.50 and a 52 week high of $2.38. The company’s 50-day moving average price is $0.81 and its 200 day moving average price is $0.83.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. As a group, research analysts expect that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HOWL. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently modified their holdings of the company. Regal Investment Advisors LLC boosted its stake in shares of Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. lifted its holdings in shares of Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares during the period. Qube Research & Technologies Ltd purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter worth about $48,000. AQR Capital Management LLC purchased a new position in shares of Werewolf Therapeutics during the 1st quarter worth about $79,000. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the period. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.